Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK's Immunology Strategy Edges Closer To Delivering

Executive Summary

GlaxoSmithKline is working to establish an immuno-inflammation portfolio and extend learnings to other therapy areas. Sirukumab could be GSK's first new product in I&I beyond Benlysta. Chief Immunology Officer Paul-Peter Tak outlined his strategy in an interview with Scrip.


Related Content

J&J Prepares For US Sirukumab Launch After Regaining Rights From GSK
Walmsley Shakes Up GSK; Cuts More Than 30 Drug Development Programs
GSK US Pharma President Jack Bailey On A “Dynamic” 2017
Pfizer Assembling New Commercial Team For Move Into Dermatology
Profile: GSK's Mature Products Head Says Innovation Still Possible In Established Drugs Business
GSK’s New CEO Designate Walmsley Fortifies Volume Growth Strategy
Too Little, Too Late For GSK/Janssen's Sirukumab in RA?
Benlysta In GSK’s Hands: A Slow-but-steady Launch, Or A Dud?
HGSI/GSK's Benlysta Gets BLySfully Clean Labeling, Escaping Feared Restrictions


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts